Literature DB >> 23448595

Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.

Kathrin I Hartmann1, Alejandra Nieto, Elizabeth C Wu, William R Freeman, Jae Suk Kim, Jay Chhablani, Michael J Sailor, Lingyun Cheng.   

Abstract

PURPOSE: To evaluate in vivo ocular safety of an intravitreal hydrosilylated porous silicon (pSi) drug delivery system along with the payload of daunorubicin (DNR).
METHODS: pSi microparticles were prepared from the electrochemical etching of highly doped, p-type Si wafers and an organic linker was attached to the Si-H terminated inner surface of the particles by thermal hydrosilylation of undecylenic acid. DNR was bound to the carboxy terminus of the linker as a drug-loading strategy. DNR release from hydrosilylated pSi particles was confirmed in the excised rabbit vitreous using liquid chromatography-electrospray ionization-multistage mass spectrometry. Both empty and DNR-loaded hydrosilylated pSi particles were injected into the rabbit vitreous and the degradation and safety were studied for 6 months.
RESULTS: The mean pSi particle size was 30×46×15 μm with an average pore size of 15 nm. Drug loading was determined as 22 μg per 1 mg of pSi particles. An ex vivo drug release study showed that intact DNR was detected in the rabbit vitreous. An in vivo ocular toxicity study did not reveal clinical or pathological evidence of any toxicity during a 6-month observation. Hydrosilylated pSi particles, either empty or loaded with DNR, demonstrated a slow elimination kinetics from the rabbit vitreous without ocular toxicity.
CONCLUSIONS: Hydrosilylated pSi particles can host a large quantity of DNR by a covalent loading strategy and DNR can be slowly released into the vitreous without ocular toxicity, which would appear if an equivalent quantity of free drug was injected.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23448595      PMCID: PMC3669596          DOI: 10.1089/jop.2012.0205

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  35 in total

1.  Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle.

Authors:  L Cheng; E Anglin; F Cunin; D Kim; M J Sailor; I Falkenstein; A Tammewar; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-05       Impact factor: 4.638

2.  Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles.

Authors:  Elizabeth C Wu; Jennifer S Andrew; Lingyun Cheng; William R Freeman; Lindsey Pearson; Michael J Sailor
Journal:  Biomaterials       Date:  2010-11-30       Impact factor: 12.479

3.  Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants.

Authors:  Paul A Sieving; Rafael C Caruso; Weng Tao; Hanna R Coleman; Darby J S Thompson; Keri R Fullmer; Ronald A Bush
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

4.  Engineering the chemistry and nanostructure of porous silicon Fabry-Pérot films for loading and release of a steroid.

Authors:  Emily J Anglin; Michael P Schwartz; Valerie P Ng; Loren A Perelman; Michael J Sailor
Journal:  Langmuir       Date:  2004-12-07       Impact factor: 3.882

5.  Polymer-lipid microbubbles for biosensing and the formation of porous structures.

Authors:  Kanaka Hettiarachchi; Abraham P Lee
Journal:  J Colloid Interface Sci       Date:  2010-01-18       Impact factor: 8.128

6.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

7.  The classification of retinal detachment with proliferative vitreoretinopathy.

Authors: 
Journal:  Ophthalmology       Date:  1983-02       Impact factor: 12.079

8.  Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.

Authors:  Kohtaro Shinohara; Minoru Tanaka; Toshiro Sakuma; Yasuhiko Kobayashi
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2003 Jul-Aug

9.  Isopropanol protein precipitation for the analysis of plasma free metanephrines by liquid chromatography-tandem mass spectrometry.

Authors:  Luke C Marney; Thomas J Laha; Geoffrey S Baird; Petrie M Rainey; Andrew N Hoofnagle
Journal:  Clin Chem       Date:  2008-08-07       Impact factor: 8.327

10.  Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.

Authors:  P Wiedemann; N Sorgente; C Bekhor; R Patterson; T Tran; S J Ryan
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-05       Impact factor: 4.799

View more
  9 in total

1.  Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

Authors:  Takeshi Iwase; Jie Fu; Tsunehiko Yoshida; Daisuke Muramatsu; Akiko Miki; Noriyasu Hashida; Lili Lu; Brian Oveson; Raquel Lima e Silva; Christopher Seidel; Ming Yang; Sheila Connelly; Jikui Shen; Bing Han; Mingsheng Wu; Gregg L Semenza; Justin Hanes; Peter A Campochiaro
Journal:  J Control Release       Date:  2013-10-12       Impact factor: 9.776

2.  Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.

Authors:  Kaihui Nan; Feiyan Ma; Huiyuan Hou; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Acta Biomater       Date:  2014-05-02       Impact factor: 8.947

3.  Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.

Authors:  Chengyun Wang; Huiyuan Hou; Kaihui Nan; Michael J Sailor; William R Freeman; Lingyun Cheng
Journal:  Exp Eye Res       Date:  2014-11-05       Impact factor: 3.467

4.  Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.

Authors:  Huiyuan Hou; Alejandra Nieto; Feiyan Ma; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  J Control Release       Date:  2014-01-11       Impact factor: 9.776

5.  Oxidation-Induced Trapping of Drugs in Porous Silicon Microparticles.

Authors:  Nicole L Fry; Gerry R Boss; Michael J Sailor
Journal:  Chem Mater       Date:  2014-03-20       Impact factor: 9.811

6.  Mechanism of erosion of nanostructured porous silicon drug carriers in neoplastic tissues.

Authors:  Adi Tzur-Balter; Zohar Shatsberg; Margarita Beckerman; Ester Segal; Natalie Artzi
Journal:  Nat Commun       Date:  2015-02-11       Impact factor: 14.919

7.  A sustained intravitreal drug delivery system with remote real time monitoring capability.

Authors:  Huiyuan Hou; Alejandra Nieto; Akram Belghith; Kaihui Nan; Yangyang Li; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Acta Biomater       Date:  2015-06-15       Impact factor: 8.947

8.  Intravitreal safety profiles of sol-gel mesoporous silica microparticles and the degradation product (Si(OH)4).

Authors:  Yaoyao Sun; Kristyn Huffman; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

9.  Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.

Authors:  David Warther; Ying Xiao; Fangting Li; Yuqin Wang; Kristyn Huffman; William R Freeman; Michael Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.